DARZALEX

DARZALEX FASPRO® Quadruplet Approved for Transplant-Ineligible Newly Diagnosed Multiple Myeloma

DARZALEX FASPRO® quadruplet approved in U.S. for transplant-ineligible newly diagnosed multiple myeloma Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination…

Read MoreDARZALEX FASPRO® Quadruplet Approved for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Lilly

Lilly’s Mirvetuximab Soravtansine Earns FDA Breakthrough Therapy Designation for Platinum-Resistant Ovarian Cancer

Lilly’s Sacituzumab Govitecan Receives U.S. FDA Breakthrough Therapy Designation for Platinum-Resistant Ovarian Cancer Eli Lilly and Company today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation…

Read MoreLilly’s Mirvetuximab Soravtansine Earns FDA Breakthrough Therapy Designation for Platinum-Resistant Ovarian Cancer
Bayer

Bayer and Vanderbilt University Medical Center Collaborate to Advance Therapies for Cardiovascular and Kidney Diseases

Bayer and Vanderbilt University Medical Center Collaborate to Advance Therapies for Cardiovascular and Kidney Diseases  Bayer and Vanderbilt University Medical Center (VUMC) today announced that they have entered a strategic…

Read MoreBayer and Vanderbilt University Medical Center Collaborate to Advance Therapies for Cardiovascular and Kidney Diseases